R. Schermuly (Bad Nauheim, Germany), M. Humbert (Clamart, France)
The inhibition of MRP4, a new target in pulmonary hypertension (PH), prevents and reverses hypoxia-induced pH in mice
Y. Hara, N. Gambaryan, Y. Sassi, P. Dorfmüller, S. Eddahibi, A. M. Lompré, M. Humbert, J. S. Hulot (Paris, Le Plessis Robinson, Clamart, France)
|  |
VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats
S. Hamidi, A. Szema, M. Mirza, S. Said (Stony Brook, Northport, United States Of America)
|   |
VIP is an endogenous inhibitor of calcineurin-NFAT signalling
S. Said, L. Gonzalez Bosc, S. Prabhakar, S. Hamidi, A. Szema (Stony Brook, Northport, Albuquerque, Frederick, United States Of America)
| |
The CXCL12/SDF-1, CXCR4, CXCR7 axis in experimental hypoxic pulmonary hypertension
N. Gambaryan, F. Perros, A. Lombet, M. Mazmanian, M. Humbert (Clamart, France)
| |
Copper restriction prevents and reverses angioproliferation in experimentally induced pulmonary arterial hypertension (PAH)
H. Bogaard, R. Natarajan, S. Mizuno, D. Kraskauskas, N. Voelkel (Richmond, United States Of America)
| |
The microRNA cluster 17/92 regulates the expression of the bone morphogenetic protein receptor type II involved in the pathogenesis of pulmonary hypertension
M. Brock, M. Trenkmann, R. E. Gay, B. A. Michel, S. Gay, M. Fischler, S. Ulrich, R. Speich, L. C. Huber (Zurich, Switzerland)
| |
Gene expression of angiogenic factors in pulmonary arteries from COPD
V. I. Peinado, M. M. Musri, M. Vives, M. Diez, S. Pizarro, E. Ferrer, R. Bastos, R. Rodriguez-Roisin, J. A. Barberà (Barcelona, Spain)
| |
Implication of bone marrow-derived c-kit positive cells in idiopathic pulmonary arterial hypertension
D. Montani, F. Perros, P. Dorfmuller, I. Durand-Gasselin, N. Gambaryan, B. Girerd, G. Simonneau, M. Humbert (Clamart, France)
| |